NICE Endorses Sparsentan for Treating Rare Kidney Disease IgA Nephropathy

Introduction

IgA nephropathy, also known as Berger’s disease, is a chronic kidney condition where the IgA protein accumulates in the kidneys, leading to inflammation and potential kidney failure. It predominantly affects individuals under 40 and is more common in men.

Treatment Recommendation

NICE’s guidance suggests Sparsentan for adults with IgAN who have a urine protein excretion of 1.0 g/day or more, or a urine protein-to-creatinine ratio (UPCR) of 0.75 g/g or more. Sparsentan functions by blocking receptors for endothelin-1 and angiotensin II, hormones that contribute to kidney damage. This action reduces proteinuria and slows disease progression.

Clinical trials indicate that Sparsentan lowers UPCR more effectively than existing treatments and may better preserve kidney function. Unlike targeted-release budesonide, which is administered for a limited duration, Sparsentan is intended for long-term use.NICE

Impact on Patients and the NHS

Approximately 18,000 individuals in England are affected by IgAN, with over 4,200 expected to benefit from this new treatment. By delaying the progression to end-stage renal disease, Sparsentan could reduce the need for dialysis or kidney transplants, thereby alleviating pressure on NHS resources.

A confidential commercial arrangement ensures that Sparsentan is available to the NHS at a discounted rate through a simple patient access scheme.

Conclusion

The approval of Sparsentan offers a significant advancement in the management of IgA nephropathy, providing patients with a long-term treatment option that may delay the progression of kidney disease and improve quality of life.

Citation:
National Institute for Health and Care Excellence. (2025, May 23). Just over 4,200 people set to benefit after NICE recommends daily pill to treat rare chronic kidney disease. NICE.